Clinical Advances and Future Directions of Oncolytic Virotherapy for Head and Neck Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Nov 14

PMID 37958464

Authors

Zhan Wang

Peng Sun

Zhiyong Li

Shaowen Xiao

Affiliations

Soon will be listed here.

Abstract

Oncolytic viruses (OVs), without harming normal tissues, selectively infect and replicate within tumor cells, to release immune molecules and tumor antigens, achieving immune-mediated destruction of tumors and making them one of the most promising immunotherapies for cancer. Many clinical studies have demonstrated that OVs can provide clinical benefits for patients with different types of tumors, at various stages, including metastatic and previously untreatable cases. When OVs are used in combination with chemotherapy, radiotherapy, immunotherapy, and other treatments, they can synergistically enhance the therapeutic effects. The concept of oncolytic virotherapy (OVT) was proposed in the early 20th century. With advancements in genetic engineering, genetically modified viruses can further enhance the efficacy of cancer immunotherapy. In recent years, global research on OV treatment of malignant tumors has increased dramatically. This article comprehensively reviews the findings from relevant research and clinical trials, providing an overview of the development of OVT and its application in the clinical treatment of head and neck cancer. The aim is to offer insights for future clinical and fundamental research on OVT.

Citing Articles

The Potential of Oncolytic Virotherapy in the Treatment of Head and Neck Cancer: A Comprehensive Review.

Spirito F, Nocini R, Mori G, Albanese M, Georgakopoulou E, Sivaramakrishnan G Int J Mol Sci. 2024; 25(23).

PMID: 39684701 PMC: 11641702. DOI: 10.3390/ijms252312990.

Ultrasound-guided intra-tumoral administration of directly-injected therapies: a review of the technical and logistical considerations.

Bitar G, Persad M, Dragan A, Alade A, Jimenez-Labaig P, Johnston E Cancer Imaging. 2024; 24(1):145.

PMID: 39456110 PMC: 11515368. DOI: 10.1186/s40644-024-00763-y.

The long-term effectiveness and mechanism of oncolytic virotherapy combined with anti-PD-L1 antibody in colorectal cancer patient.

Zhang H, Ren Y, Wang F, Tu X, Tong Z, Liu L Cancer Gene Ther. 2024; 31(9):1412-1426.

PMID: 39068234 PMC: 11405277. DOI: 10.1038/s41417-024-00807-2.

Adenoviral Vector System: A Comprehensive Overview of Constructions, Therapeutic Applications and Host Responses.

Park A, Lee J J Microbiol. 2024; 62(7):491-509.

PMID: 39037484 DOI: 10.1007/s12275-024-00159-4.

Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers.

Meci A, Goyal N, Slonimsky G Cancers (Basel). 2024; 16(4).

PMID: 38398094 PMC: 10887076. DOI: 10.3390/cancers16040703.

References

Hwang J, Hong J, Yun C . Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials. Int J Mol Sci. 2020; 21(22). PMC: 7697902. DOI: 10.3390/ijms21228627. View

Raja J, Ludwig J, Gettinger S, Schalper K, Kim H . Oncolytic virus immunotherapy: future prospects for oncology. J Immunother Cancer. 2018; 6(1):140. PMC: 6280382. DOI: 10.1186/s40425-018-0458-z. View

Gordon K, Smyk D, Gulidov I, Golubev K, Fatkhudinov T . An Overview of Head and Neck Tumor Reirradiation: What Has Been Achieved So Far?. Cancers (Basel). 2023; 15(17). PMC: 10486419. DOI: 10.3390/cancers15174409. View

Fu X, Tao L, Wu W, Zhang X . Arming HSV-Based Oncolytic Viruses with the Ability to Redirect the Host's Innate Antiviral Immunity to Attack Tumor Cells. Mol Ther Oncolytics. 2020; 19:33-46. PMC: 7530262. DOI: 10.1016/j.omto.2020.09.002. View

OMeara C, Jafri Z, Khachigian L . Immune Checkpoint Inhibitors, Small-Molecule Immunotherapies and the Emerging Role of Neutrophil Extracellular Traps in Therapeutic Strategies for Head and Neck Cancer. Int J Mol Sci. 2023; 24(14). PMC: 10380483. DOI: 10.3390/ijms241411695. View

Kumai T, Shinomiya H, Shibata H, Takahashi H, Kishikawa T, Okada R . Translational research in head and neck cancer: Molecular and immunological updates. Auris Nasus Larynx. 2023; 51(2):391-400. DOI: 10.1016/j.anl.2023.08.006. View

Mace A, Ganly I, Soutar D, Brown S . Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Head Neck. 2008; 30(8):1045-51. DOI: 10.1002/hed.20840. View

Pasin F, Mascalchi Calveri M, Calabrese A, Pizzarelli G, Bongiovanni I, Andreoli M . Oncolytic effect of SARS-CoV2 in a patient with NK lymphoma. Acta Biomed. 2020; 91(3):ahead of print. PMC: 7716983. DOI: 10.23750/abm.v91i3.10141. View

Ottaiano A, Scala S, DAlterio C, Trotta A, Bello A, Rea G . Unexpected tumor reduction in metastatic colorectal cancer patients during SARS-Cov-2 infection. Ther Adv Med Oncol. 2021; 13:17588359211011455. PMC: 8107669. DOI: 10.1177/17588359211011455. View

10.

Kaufmann J, Nettelbeck D . Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond. Trends Mol Med. 2012; 18(7):365-76. DOI: 10.1016/j.molmed.2012.04.008. View

11.

Velazquez-Salinas L, Naik S, Pauszek S, Peng K, Russell S, Rodriguez L . Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV. Hum Gene Ther Clin Dev. 2017; 28(2):108-115. PMC: 5583557. DOI: 10.1089/humc.2017.015. View

12.

Buchler T, Fiser L, Benesova J, Jirickova H, Votrubova J . Spontaneous Regression of Metastatic Renal Cell Carcinoma after SARS-CoV-2 Infection: A Report of Two Cases. Curr Oncol. 2021; 28(5):3403-3407. PMC: 8482236. DOI: 10.3390/curroncol28050294. View

13.

Larson C, Oronsky B, Reid T . AdAPT-001, an oncolytic adenovirus armed with a TGF-β trap, overcomes resistance to PD-L1-immunotherapy. Am J Cancer Res. 2022; 12(7):3141-3147. PMC: 9360241. View

14.

Qiu S, Shan X, Kang Y, Ding M, Zhang L, Cai Z . Accurate occlusion-driven maxillary reconstruction with deep circumflex iliac artery flap using computer-assisted techniques and intraoral anastomosis: a case series. Int J Oral Maxillofac Surg. 2022; 52(7):744-752. DOI: 10.1016/j.ijom.2022.10.016. View

15.

Wang Y, Jin J, Li Y, Zhou Q, Yao R, Wu Z . NK cell tumor therapy modulated by UV-inactivated oncolytic herpes simplex virus type 2 and checkpoint inhibitors. Transl Res. 2021; 240:64-86. DOI: 10.1016/j.trsl.2021.10.006. View

16.

Burton C, Bartee E . Syncytia Formation in Oncolytic Virotherapy. Mol Ther Oncolytics. 2020; 15:131-139. PMC: 6931088. DOI: 10.1016/j.omto.2019.09.006. View

17.

Doronin K, Shashkova E, May S, Hofherr S, Barry M . Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther. 2009; 20(9):975-88. PMC: 2829283. DOI: 10.1089/hum.2009.028. View

18.

Krabbe T, Altomonte J . Fusogenic Viruses in Oncolytic Immunotherapy. Cancers (Basel). 2018; 10(7). PMC: 6070779. DOI: 10.3390/cancers10070216. View

19.

Challenor S, Tucker D . SARS-CoV-2-induced remission of Hodgkin lymphoma. Br J Haematol. 2021; 192(3):415. DOI: 10.1111/bjh.17116. View

20.

Zhu Z, McGray A, Jiang W, Lu B, Kalinski P, Guo Z . Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways. Mol Cancer. 2022; 21(1):196. PMC: 9554963. DOI: 10.1186/s12943-022-01664-z. View